UroGen Pharma Ltd. Cash Flow Statement
URGN / Health Care|10 years of annual SEC 10-K data (FY2016-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 10 fiscal years. All figures from audited SEC 10-K filings.
UroGen Pharma Ltd. used $162M in operating cash flow and negative free cash flow of $163M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$153.5M | -$54.3M | -$109.8M | -$110.8M | -$110.8M | -$105.1M | -$20.0M | -$75.7M | -$20.0M | -$1.9M |
| Depreciation & Amortization | $307.0K | $802.0K | $924.0K | $831.0K | $831.0K | $300.0K | $200.0K | $400.0K | $200.0K | $200.0K |
| Operating Cash Flow | -$162.4M | -$76.4M | -$87.6M | -$84.9M | -$84.9M | -$71.0M | -$9.6M | -$37.3M | -$9.6M | $4.2M |
| Capital Expenditures | $289.0K | $194.0K | $254.0K | $752.0K | $752.0K | $325.0K | $271.0K | $560.0K | $271.0K | $695.0K |
| Free Cash Flow | -$162.7M | -$76.6M | -$87.8M | -$85.6M | -$85.6M | -$71.3M | -$9.8M | -$37.9M | -$9.8M | $3.5M |
| FCF Margin | -148.2% | -199.8% | -136.5% | -178.3% | -178.3% | -396344.4% | -120.6% | -3359.4% | - | 19.9% |